Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer


Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive , human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease progressed on or after prior endocrine therapy. In the study, there was a numerical improvement in OS of nearly seven months with IBRANCE plus fulvestrant compared to placebo plus fulvestrant, although this difference did not reach the prespecified threshold for statistical significance .



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога